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Decay-accelerating factor (DAF) ~ is a membrane protein that inhibits amplifi- 
cation of the complement cascade on cell surfaces.  By binding to C3b or C4b 
complement fragments  that accidentally deposit on  the  cell  membrane,  DAF 
blocks the assembly of both the classical and alternative C3 and C5 convertases 
(1-3).  In  this  manner,  DAF  protects  host  cells  from  damage  by  autologous 
complement. 
DAF  is  deficient  in  a  rare  acquired  disorder  of  blood  cells,  paroxysmal 
nocturnal hemoglobinuria (PNH) (4, 5), characterized by increased sensitivity of 
erythrocytes to complement-mediated lysis  (6).  The  DAF-deficient blood cells 
probably originate from the expansion of abnormal bone marrow clones (7, 8), 
but the nature of the molecular defect is unknown. Other membrane abnormal- 
ities  have  been  found  in  PNH,  including the  absence  of acetylcholinesterase 
(ACHE) in the population of complement-sensitive erythrocytes (9). 
These two apparently unrelated proteins, DAF and ACHE, share the property 
of being able, in a  purified form, to reincorporate into the lipid bilayer of cell 
membranes or into phospholipid vesicles (3, 10, 11). The amphipathic properties 
of AChE are  known  to be due to an  unusual  type of membrane anchor,  the 
diacylglycerol moiety of a  phosphatidylinositol (PI) molecule that is covalently 
attached to the protein (11, 12). The structure of this membrane-seeking domain 
was revealed,  in part,  by the observation that  AChE is released from the cell 
surface by phosphatidylinositol-specific phosholipase C (PIPLC) (13,  14). In view 
of the above-mentioned similarity between the amphipathic properties of DAF 
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and ACHE, as well as the fact that they are both absent from a  clonal disorder, 
we studied the sensitivity of DAF to PIPLC. 
Materials and  Methods 
Buffers, Reagents, Complement Components, and Red Cell Hemolytic Intermediates.  Buffers 
for the  enzymatic treatments  were  Dulbecco's PBS,  or  Hepes-buffered isotonic saline 
(HBS) (0.154  M  NaCI;  10  mM  Hepes,  pH  7.4).  In the  hemolytic assay, buffers were 
isotonic veronal-buffered saline (DGVB  ÷+) (2.5 mM veronal, pH 7.5; 73 mM NaCI; 2.5% 
dextrose;  0.15  mM  CaCI2;  0.5  mM  MgCI~; and  0.1%  gelatin) and the  metal-chelating 
veronal buffer (GVB-EDTA) prepared as above, but without dextrose, CaCI2 or MgCI~, 
and supplemented with  I 0 mM EDTA. For hypotonic lysis a phosphate buffer was used 
(0.005 M sodium phosphate, pH 7.5; 0.001  M EDTA; 50 mM PMSF [reference 2]). C1, 
C2,  C4,  and C3-9  (C-EDTA) were prepared as described previously (3).  EAC142  cells 
were prepared from antibody (IgG)-sensitived sheep erythrocytes (EA),  by sequentially 
reacting guinea pig C1 and human C4 and C2 with EA (3). 
Phospholipase C (Type I from Clostridium perfringens), BSA (RIA grade), OVA (grade 
V), PMSF, and soybean trypsin inhibitor (SBTI) were purchased from Sigma Chemical 
Co., St.  Louis, MO. Trypsin was purchased from Cooper Biomedical, Inc., Malvern, PA. 
Hemolytic Assay.  Inhibition of the classical  pathway C3-convertase (C4b2a) was quan- 
titated as described by Nicholson-Weller et al. (2). Briefly, EAC 142 cells containing ~ 1.5 
C4b2a hemolytic sites per cell were allowed to decay for 15 min at 30°C in the presence 
or absence of various concentrations of DAF.  Residual C4b2a sites were developed by 
incubation of the intermediates with C-EDTA for 1 h at 37°C. 
Preparation of PIPLC.  PIPLC was prepared from Staphylococcus aureus as previously 
described (15). Briefly, culture supernatant was first centrifuged, the pH adjusted to 5.5, 
and the supernatant  loaded onto a  column of Amberlite CG-50 (Sigma Chemical Co.). 
The column was eluted with a linear salt gradient, the eluate concentrated by ammonium 
sulfate precipitation (90% saturation), and dialyzed. The concentrate was then chromat- 
ographed on Sephadex G-75-preequilibrated in Tris-acetate buffer. Purity as judged by 
SDS-PAGE was ~90%. The final preparation was lyophilized and stored at 4°C. 
Purification ofmAbs.  Two mAbs were used, IA10 (IgG2a), and IIH6 (IgG1) (8). They 
were purified from ascites fluids by precipitation with 50%-saturated ammonium sulfate, 
followed by DEAE-Sephacel chromatography.  Polyclonal anti-DAF antibody was pre- 
pared by immunization of rabbits with purified DAF. 
Two-Site Immunoradiometric Assay (IRMA)for DAF.  This was performed essentially as 
described previously (8).  Briefly, plastic plates (96-U-bottomed wells;  Becton, Dickinson 
& Co., Oxnard, CA) were coated with 20 #g/ml of anti-DAF monoclonal IA 10 diluted in 
PBS.  The wells were incubated with the DAF-containing extracts, washed three  times 
with  PBS  containing  1%  BSA  and  0.02%  NaN3  (AZ),  and  then  incubated  with  the 
revealing antibody, ~SI-labeled anti-DAF mAb (IIH6). After being washed, the wells were 
counted. The amount of DAF was calculated by comparison of the values in the samples 
with the values in the standard curve obtained using purified DAF. 
Immunopurification of DAF.  3 mg of purified mAb to DAF,  (IA10) or an irrelevant 
mAh,  were  coupled  to  CNBr-activated  Sepharose  CL-4B (Pharmacia  Fine  Chemicals, 
Piscataway, N  J) according to the manufacturer's instructions. 
DAF was isolated by affinity chromatography from the supernatant of PIPLC-treated 
human erythrocytes (huE),  or from the solubilized extracts of erythrocyte membranes. 
To remove materials that bound nonspecifically to the beads, the supernatants were first 
incubated by rotation at room temperature for 1 h with  100-200 ~1 of sepharose beads 
bearing the irrelevant mAb; the supernatant was then incubated for an additional  2  h 
with 50 tA of beads bearing the monoclonal anti-DAF antibody. The beads were washed 
with 400/A of PBS containing 0.001% NP-40 and the bound DAF was eluted by incubation 
for  1 h  at room temperature with PBS-0.001%  NP-40 containing 0.1  M triethylamine, 
pH 11.5 (16).  The eluate was neutralized by the addition of 1 M Tris-HCl, pH 7.4. DAF 
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For the large scale preparation of DAF, the starting materials were detergent extracts 
from erythrocyte membranes. These were subjected to affinity chromatography as above, 
and  then  further  purified  by  HPLC  on  a  TSK-3000  SW  gel-filtration  column  (LKB 
Produkter,  Bromma,  Sweden).  The  final  preparations  of DAF  were  >90%  pure,  as 
determined by silver staining. Details of this procedure will be published elsewhere (Davitz, 
M. A., and V. Nussenzweig, manuscript in preparation). 
Preparation of Blood Cells.  Citrated blood was centrifuged at 400 g for 10 rain at 4 ° C. 
The plasma and buffy coat were removed and the huE washed four times with PBS before 
use. huE were stored for up to 1 wk at 4°C after venipuncture.  Mononuclear cells were 
isolated by centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals). Neutrophils were 
obtained by centrifugation of fresh citrated  blood on FicolI-Paque followed by dextran 
sedimentation (17). 
PIPLC Treatment of Cells.  hue (109/ml) were suspended in HBS containing  1 mg/ml 
OVA.  PIPLC  was  then  added  (concentration  specified  in  the  text),  and  the  mixture 
incubated at 37 °C (time specified in the text). After incubation, the cells were pelleted by 
centrifugation for 30 s and the supernatant removed. The cells were washed twice in the 
same buffer and incubated for  15 rain at room temperature  in PBS containing 1% NP- 
40 with  1 mM PMSF; insoluble material was removed by centrifugation at  12,000 g for 
15  min.  DAF  in  both  the  supernatants  and  the  solubilized  membranes  from  PIPLC 
treatment was assayed by IRMA. 
Mononuclear  cells  and  neutrophils  (2-5  ×  108  cells/ml)  were  suspended  in  PBS 
containing 1% BSA and 0.1%AZ; PIPLC (final concentration 15 #g/ml) was then added. 
The  cells  were  incubated  for  15  min  at  37°C,  pelleted  by  centrifugation,  and  the 
supernatant removed. The cells were washed twice with the same buffer and analyzed for 
the  presence  of DAF by  immunofluorescence  using  a  FACS.  Alternatively,  DAF was 
assayed in the supernatant and solubilized pellet by IRMA as described above. 
In all experiments duplicate samples were processed and the results represent the mean 
values. Variation around the mean was always <10%. Negative controls, in which PIPLC 
was omitted, were included in each experiment. 
Reineorporation  of 125I-labeled DAF into  huE (3).  Purified  membrane  DAF or  DAF 
isolated from the supernatants of erythrocytes treated with PIPLC (DAF-S) were labeled 
7  125  125  to similar specific activities (1-2 ×  10  cpm/#g) with  I.  143 ng of  I  DAF or DAF-S 
were  incubated  with  1.7  ×  l0 s  hue  for  I  h  at  37°C  in  a  volume  of 120  #l  of HBS 
containing 1 mg/ml OVA. The cells were overlayed on FCS, pelleted by centrifugation, 
and then washed three times in HBS containing 1 mg/ml OVA to remove nonspecifically 
adherent material. 
Trypsinization of huE.  A suspension of huE in HBS (101°]ml) mixed with trace amounts 
of '25I surface-labeled huE was incubated for 15 min at 37 °C in a volume of 300 gl, either 
with trypsin (150 t~g/ml)  or the same concentration of trypsin mixed with 400 ~g/ml of 
SBTI.  After  incubation,  an  excess  of SBTI  was  added  to the  tube  containing trypsin 
alone. The cells were pelleted, the supernatant removed, and the cells washed with HBS. 
Total cpm released in the supernatant was determined in a gamma counter; DAF released 
was quantitated by IRMA. Samples of the cells were incubated for 15 min at 37 °C, either 
with PIPLC (15 t~g/ml) or buffer alone. The cells were pelleted, and the supernatant and 
pellet  processed  as  described  above  to  determine  the  amount  of DAF  and  released 
radioactive material. 
FACS Analysis of Surface DAF.  Mononuclear cells and neutrophils were treated with 5 
#g/ml  of mAb  IA10,  washed  by centrifugation,  and  then  incubated  with  fluorescein- 
conjugated sheep F(ab')~ anti-mouse  IgG heavy and  light chains (Cappel  Laboratories, 
Cochranville, PA) (8). After washing, the cells were analyzed by FACS. Control cells were 
treated with irrelevant mAb of the same subclass and then stained as above. 
Radiolabeling.  Proteins were radiolabeled with 125I by Iodogen (Pierce Chemical Co., 
Rockford,  IL).  Unbound  1~5I was  removed  by gel  filtration  through  Sephadex  G-25 
(Pharmacia Fine Chemicals). 
The surface membrane of hue was labeled with ~2~I using Iodogen. Unbound ~2"~I was DAVITZ  ET  AL.  1153 
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FIGURE  1.  Release of DAF by PIPLC. huE were incubated for 1 h  at 37°C with PIPLC at 
the concentrations noted. DAF was assayed in the supernatant and in the cell extracts by 
IRMA. All titrations were done in duplicate. There was a  maximum of 11-12% release of 
DAF by PIPLC. 
removed by overlaying the cells on FCS, centrifuging, and washing the pelleted cells with 
HBS containing 1 mg/ml OVA. 
SDS-PAGE, Radioautography, and Western Blotting.  SDS-PAGE was performed as de- 
scribed by Laemmli (18). Stacking gels of 3% and separating  gels of 7.5% were used. 
Apparent molecular weights were determined by reference to standards  (Bethesda Re- 
search Laboratories,  Gaithersburg,  MD). Gels were fixed by methanol/acetic  acid and 
then stained with either Coomassie Blue or silver stain (Bio-Rad Laboratories, Cambridge, 
MA). Gels for radioautography were  exposed at -70°C  using X-OMAT  XAR-5 film 
(Eastman Kodak Co., Rochester,  NY). Western blotting was performed as described by 
Towbin et al. (19). 
Results 
DAF  is  Released from  huE  by PIPLC.  huE  were  incubated  with  increasing 
concentrations of PIPLC at 37°C for  1 h.  DAF was then assayed both in the 
supernatant and in the membrane extracts of treated huE by IRMA. DAF was 
released by the enzyme in a dose-dependent fashion (Fig.  1).  In several experi- 
ments, a  maximum of 10-12%  of the total membrane DAF was released at a 
PIPLC concentration of 15 #g/ml. The amount of released DAF did not increase 
significantly when the enzyme concentration was  17-fold greater, or when the 
incubation time was prolonged for up to 3 h. Specificity of the release by PIPLC 
was shown by the absence of DAF in the supernatants of huE treated with a 
broad specificity phospholipase C (15 gg/ml) from C. perfringens. 
The fact that only 10-12%  of the surface DAF was susceptible to release by 
PIPLC, suggested that there was either a  PIPLC-resistant population of DAF 
molecules on huE, or that some of the membrane DAF was not accessible to the 
enzyme. To distinguish between these possibilities, we reincorporated purified 
~5I-iabeled DAF into huE and then treated the cells with the enzyme as above. 
Only  15.3%  of the  reincorporated  DAF counts  were specifically released  by 
PIPLC. 
We also pretreated huE with trypsin to remove part of the surface molecules 
that  could  potentially interfere with  PIPLC activity, and  then  measured  the 
release of DAF by this enzyme. To facilitate interpretation of the results, a small 
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TABLE  I 
Effect of Trypsinization  of Human Erythrocytes on the Release of DAF 
DAF*  cpm  Secondary  DAF*  cpm 
Primary treatment  released  released  treatment  released  released 
ng  %  ng  % 
Trypsin  1.1  28.7  PIPLC  5.1  0.2 
Trypsin + SBTI  0.0  2.7  PIPLC  5.6  0.9 
* Determined by IRMA. 
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FIGURE 2.  FACS  analysis of PIPLC-treated  lymphocytes and monocytes. Peripheral  blood 
mononuclear  cells isolated on Ficoll-Paque were treated with PIPLC (15 t~g/ml). The cells 
were treated with a single anti-DAF monoclonal, IA10, and then stained with fluorescein- 
conjugated sheep F(ab')~ anti-mouse IgG. A nonrelevant monoclonal of the same subclass was 
used as a negative control. (A) lymphocytes; (B) monocytes. Solid lines, fluorescence of cells 
treated with anti-DAF mAb; dashed lines, fluorescence of cells treated with a control mAb. 
The mean fluorescence intensities of lymphocytes and monocytes treated with antibodies to 
DAF were 181 and 410 (left), respectively; after PIPLC treatment (right) the mean fluorescence 
intensities were: lymphocytes, 33.7 and monocytes, 132.7. The fluorescence intensity of the 
control cells did not change significantly after PIPLC treatment. 
rocytes. The mixture of labeled and unlabeled cells was first treated with trypsin 
or with trypsin inactivated by SBTI, as described in the Materials and  Methods 
section.  Trypsin  released  26%  of the  surface  cell-associated  counts  (Table  I), 
but only 1.1  ng of DAF (~2% of the total surface DAF). The trypsin-treated and 
control cells were then  incubated  with  PIPLC (15  gg/ml) for  15  min at  37°C. 
The  specific  release  of  labeled  surface  molecules  by  PIPLC  did  not  differ 
significantly  in  the  two groups  and  was <1%.  There  was no  difference  in  the 
amounts of DAF released by PIPLC in cells treated with trypsin or controls, i.e., 
5.1  ng vs. 5.6 ng, which corresponds to -10%  of the surface DAF. 
Release of DAF from Lymphocytes and Neutrophils  by PIPLC.  Next we studied 
the effect of PIPLC on DAF from the surface of peripheral blood mononuclear 
cells and neutrophils.  The cells were incubated with  15 gg/ml of PIPLC for  15 
rain at 37 °C, and DAF assayed by IRMA in both the supernatants and extracts 
of membranes from the  treated cells.  The amount  of DAF released by PIPLC 
corresponded  to  80  and  53%  of the  total  DAF  that  could  be  extracted  from 
mononuclear cells and  neutrophils,  respectively.  To determine  the  proportion 
of membrane DAF that was removed by PIPLC, we subjected the cells to FACS 
analysis after treatment with mAbs to DAF, followed by staining with fluorescein- DAVITZ  ET  AL.  1155 
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FIGURE  3.  FACS analysis of PIPLC-treated neutrophils. Purified neutrophils were treated 
with PIPLC (30 #g/ml) for varying periods of time at 37 ° C. Aliquots were removed at 15 (B), 
30 (C), and 45 (D) min and the cells processed for FACS as described above. Control cells 
were incubated without PIPLC for 45 rain at 37°C (A).  Solid lines, cells treated with anti- 
DAF mAb; dashed lines, control cells treated with a  nonrelevant mAb of the same subclass. 
(E) The mean fluorescences of cells analyzed in A-D were plotted against the incubation times: 
dashed line, incubation in the absence of PIPLC;  solid line, incubation in the presence of 
PIPLC. There was a decrease of ~60% in the mean fluorescence after treatment with PIPLC 
for 30 rain. 
conjugated sheep F(ab')2 anti-mouse IgG. The mean fluorescent intensities of 
lymphocytes and monocytes decreased by ~80%  (Fig.  2A) and 70%  (Fig.  2B), 
respectively, in the PIPLC-treated cells as compared with controls in which the 
primary antibody was a nonrelevant mAb of the same subclass. Neutrophils were 
incubated with 30 #g/ml of PIPLC at 37°C for 15, 30, and 45 rain (Fig.  3, B- 
D,  respectively). The  decrease in  fluorescence intensity reached a  plateau  of 
~60% after 30 rain (Fig. 3E). PIPLC had no effect on complement receptor 1 
(CRI)  of lymphocytes or erythrocytes as determined by FACS analysis using 
mAbs to  CR1  for the primary antibody (data not shown).  Additionally, with 
respect to erythrocytes there was no evidence by FACS of a distinct subpopulation 
of PIPLC-sensitive hue (data not shown). 
Properties of Released DAF.  To examine the effect of PIPLC on the structure 
of DAF, hue were treated with PIPLC and the released material (DAF-S) was 
purified from the supernatants by affinity chromatography. DAF-S migrated on 
SDS-PAGE as a  single band with an Mr of 67,000,  slightly smaller than that of 
untreated  DAF  (Fig.  4,  lane  2).  By Western  blotting  we confirmed that  the 
smaller molecule was indeed DAF (Fig. 4, lane 4). 
We then compared the ability of native DAF and  DAF-S to  accelerate the 
decay-of preformed C3-convertase. EAC142 cells, with 1.5 hemolytic sites/cell, 
were incubated with increasing concentrations of DAF-S or DAF. After incuba- 
tion at 30°C, the cells were washed and residual C4b2a sites developed with C- 
EDTA.  As  shown in  Fig.  5,  DAF  inhibited  C4b2a  sites in  a  dose-dependent 1156  DECAY-ACCELERATING FACTOR-RELEASE  FROM  CELL  MEMBRANE 
FIGURE 4.  Effect  of  PIPLC  on  the  structure  of  DAF.  DAF-S  was  isolated  by  affinity 
chromatography from the supernatants of PIPLC-treated huE. Purified DAF and DAF-S were 
labeled to similar specific activities with 1~5I and subjected to SDS-PAGE followed by radioau- 
tography. Lane 1, DAF; lane 2, DAF-S. Unlabeled, purified DAF and DAF-S were subjected 
to SDS-PAGE, followed by Western blotting using a polyclonal rabbit anti-DAF antibody; lane 
3, DAF; lane 4, DAF-S. DAF-S is slighity smaller than DAF. The band with 150,000 Mr shown 
in lane 3 is DAF-II, a recently discovered form of red cell DAF (Kinoshita, T., S. I. Rosenfeld, 
and V. Nussenzweig, manuscript in preparation). 
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FIGURE 5.  Comparison of DAF and DAF-S in their ability to accelerate the decay of the C3 
convertase,  C4b2a.  Percent  inhibition of the  hemolytic activity (Z)  of the  C3  convertase, 
C4b2a, is plotted against increasing DAF concentration. At I  ng/ml DAF inhibited ~20% of 
the C4b2a sites,  while DAF-S had no effect at a concentration of 20 ng/m]. 
fashion, while DAF-S showed no significant inhibitory effect. The PIPLC treat- 
ment also affected the ability of DAF to reincorporate into the cells.  In these 
experiments huE were incubated with purified ~SI-labeled DAF or DAF-S. The 
cells were washed, the membranes solubilized in sample buffer, and then sub- 
jected to SDS-PAGE followed by radioautography. As shown, only native DAF 
reincorporated into the membrane (Fig. 6, lane 2). 
Discussion 
A new family of proteins anchored to the membrane by PI has recently been 
identified;  the  group  includes  AChE  (11-14),  alkaline  phosphatase  (20),  5'- 
nucleotidase (21, 22), Thy-1 (23, 24), the variant surface glycoprotein of African 
trypanosomes (VSG) (25,  26), a  merozoite surface antigen of Plasmodium falci- 
parum (27), and a major membrane protein of Leishmania parasites (M. J. Turner, 
personal communication). The role of PI in the hydrophobic attachment of these DAVITZ  ET  AL.  1157 
FIGURE 6.  Incorporation of DAF or DAF-S into huE.  143 ng of l~sI DAF and DAF-S were 
incubated for 1 h at 37°C  with 1.7 X l0  s huE in HBS containing  1 mg/ml OVA. After 
incubation, the cells were centrifuged through FCS and washed three dmes with the same 
buffer. The cells were lysed by incubation at room temperature for 15 rain with 800 t~l of a 
hypotonic phosphate buffer (0.005 M sodium phosphate buffer, pH 7.5; 0.001 M EDTA; 50 
mM PMSF). The membranes were isolated by centrifugation for 10 min at 12,000 g, washed 
once  in the same buffer,  and then solubilized directly in SDS-PAGE sample buffer.  The 
samples were boiled for  10 min and the insoluble material removed by centrifugation at 
100,000 rpm for 5 min in a T 1-100 micro-ultracentrifuge (Beckman Instruments, Inc., Palo 
Alto, CA). Samples were then subjected to SDS-PAGE  and radioautography. Lane 1, hue + 
1~I DAF-S; lane 2, huE +  '2~I DAF. DAF readily reincorporates into the red cell, whereas 
DAF-S is unable to reincorporate. 
proteins to the cell surface has been demonstrated by enzymatic studies showing 
their release from the membrane by treatment of the cells with PIPLC, as well 
as  by chemical analysis  of the  membrane  anchors  of several of these  proteins 
(28). The detailed analysis of the membrane-anchoring domain of VSG, shows 
that  it  is  attached  via  the  carboxyl terminus  to  ethanolamine,  which  is  linked 
sequentially to an oligosaccharide (29,  30) and glucosamine; the protein-carbo- 
hydrate complex is anchored to the cell surface by PI (26). The evidence to date 
strongly suggests that the other proteins anchored by this mechanism are attached 
to PI by similar structures on their carboxyl terminus (28). 
Here we present evidence that DAF's membrane anchor is PI. DAF is released 
from the membrane of peripheral blood red cells and leukocytes by PIPLC. The 
release is highly selective, since treatment with a  broad-specificity phospholipase 
C  or with  trypsin was  ineffective. Furthermore, while PIPLC released <1%  of 
the counts from ~25I-labeled erythrocytes, it removed 10-12% of the cell surface 
DAF. PIPLC released 70-80% of membrane DAF from peripheral blood mono- 
nuclear cells and 60% of the DAF from the surface of neutrophils. 
The reason for resistance of part of the surface DAF to PIPLC is not known. 
Although only ~10% of AChE from human red cells is released by PIPLC (31), 
available chemical evidence suggests that the protein is anchored exclusively by 
PI  (12).  Perhaps  PIPLC  does  not  have  access  to  all  the  PI-anchored  DAF 
molecules. This does not appear to be the case for DAF, since removal of part 
of the red cell surface proteins by trypsinization before treatment with  PIPLC 
did  not  increase  the  release  of DAF.  More importantly,  only  15%  of the  red 
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was  released by  PIPLC.  On  the basis  of the  reasonable  assumption  that  the 
incorporated molecules are randomly distributed within the erythrocyte mem- 
brane and therefore equally accessible to PIPLC, it appears that red cell DAF is 
structurally heterogeneous. For example, part of the red cell DAF molecules 
may be  secondarily modified on  the  membrane, rendering them resistant  to 
PIPLC, or alternatively, a portion of the DAF molecules may not be anchored 
by PI. 
The finding that DAF and AChE share similar, if not identical, membrane- 
spanning domains is relevant to the pathogenesis of PNH. The absence of these 
two otherwise functionally unrelated proteins in  the affected cells from PNH 
patients suggests that the molecular defect in this disease may lie in the biosyn- 
thetic pathways leading to attachment of PI  to  the polypeptide chain,  in  the 
transport of these proteins to the surface membrane, or in their release by the 
action of endogenous phospholipases. According to this hypothesis, other mem- 
brane  molecules, e.g.,  alkaline phosphatase,  and  5'-nucleotidase,  that are an- 
chored by PI (20-22), should also be deficient in PNH cells. In fact, Craddock 
et al. reported that the levels of leukocyte alkaline phosphatase are decreased in 
the patient's leukocytes (32). 
By SDS-PAGE, DAF-S is slightly smaller than the membrane form. DAF and 
DAF-S cannot be distinguished antigenically; however, DAF-S has lost the ability 
to significantly enhance the decay-dissociation of the C3 convertase, C4b2a,  as 
well as its ability to reincorporate into cell membranes. On the basis of prior 
evidence showing that DAF can only inhibit C3-convertase activity endogenously 
within the same cell membrane (3), it is likely that the lack of inhibitory activity 
of DAF-S is causally related to its inability to insert into membranes. 
The  functional  significance  of the  PI  anchor  is  not  known.  It  has  been 
suggested that it may be energetically more favorable than a membrane-spanning 
hydrophobic polypeptide sequence (28).  We speculate that the PI anchor may 
increase the rate of lateral  mobility of the attached polypeptides in  the lipid 
bilayer. This would be advantageous in the case of DAF, which must move freely 
and rapidly in  the membrane to encounter the randomly distributed C3b and 
C4b deposited fragments and inhibit their hemolytic activity (3). Further studies 
using the fluorescence photobleaching recovery method (33)  to  measure  the 
rates of lateral diffusion of the PI-anchored protein molecules are necessary to 
substantiate this hypothesis. 
From  a  practical  standpoint,  the  specific release  of DAF  by  PIPLC  could 
provide a  novel approach for altering the complement sensitivity of cells. Au- 
tologous bone marrow transplantation depends on the elimination of tumor cells 
from the marrow (34, 35). Classically, leukemic cells are eliminated by successive 
rounds of treatment of the marrow with mAb and  rabbit  complement. This 
method results in >99%  removal of residual tumor cells; nonetheless, pretreat- 
ment  with  PIPLC  may amplify the  effects of the  cascade on  the  surface of 
antibody-sensitized cells. 
Summary 
Decay-accelerating  factor (DAF) is a 70,000 Mr membrane protein that inhibits 
amplification of the complement cascade on the cell surface, and protects cells DAVITZ ET  AL.  1159 
from damage.  Purified DAF can be reincorporated  into the membrane of red 
cells and is functional. DAF is deficient in paroxysmal nocturnal hemoglobinuria 
(PNH), a disease characterized by increased sensitivity of erythrocytes to comple- 
ment lysis. 
We show here  that  DAF  is part  of a  newly described  family of membrane 
proteins  anchored  to  the  lipid  bilayer  by means  of phosphatidylinositol  (PI). 
Treatment  with  PI-specific phospholipase  C  (PIPLC) releases  70-80,  60,  and 
10% of cell surface DAF from mononuclear cells, neutrophils, and erythrocytes, 
respectively. The  PIPLC-released  DAF (DAF-S) is slightly smaller (67,000 Mr) 
than the membrane form. DAF and DAF-S cannot be distinguished antigenically. 
Furthermore,  DAF-S has lost its ability to significantly inhibit the C3-convertase, 
as well as its ability to  incorporate  into  cell  membranes.  Since  DAF can  only 
inhibit C3-convertase endogenously, i.e., within the membrane of the same cell, 
it is likely that the loss of activity of DAF-S is causally related to its inability to 
reincorporate in the lipid bilayer. As shown by others, the complement-sensitive 
red cells from PNH patients lack acetylcholinesterase, which is also anchored to 
the membrane  by PI (9).  Thus it is possible that  the molecular defect in  PNH 
lies in the biosynthetic pathways leading to the attachment of PI to the polypep- 
tide chains,  in the transport of these proteins to the surface, or in their release 
by the action of endogenous phospholipases. 
From  a  practical  standpoint  the  specific  release  of DAF  by  PIPLC  could 
facilitate  killing  of tumor  cells  by amplifying  the  effects of the  complement 
cascade on the surface of antibody-sensitized cells. 
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